Assay development for histone methyltransferases

Assay and Drug Development Technologies

Volumn 11, Issue 4, 2013, Pages 227-236

  Horiuchi, Kurumi Y ^a   Eason, Mia M ^a   Ferry, Joseph J ^a   Planck, Jamie L ^a   Walsh, Colin P ^a   Smith, Robert F ^a   Howitz, Konrad T ^a   Ma, Haiching ^a  

^a REACTION BIOLOGY CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE H3; HISTONE H4; HISTONE METHYLTRANSFERASE; PROTEIN ARGININE METHYLTRANSFERASE; RADIOISOTOPE; S ADENOSYLMETHIONINE; SURAMIN;

ARTICLE; CANCER GENETICS; CANCER RESEARCH; DNA LIBRARY; DNA MODIFICATION; DNA SEQUENCE; ENZYME ASSAY; ENZYME KINETICS; EPIGENETICS; GENE MUTATION; HIGH THROUGHPUT SCREENING; HUMAN; IC 50; NUCLEOSOME; NUCLEOTIDE SEQUENCE;

DRUG DISCOVERY; ENZYME ACTIVATION; ENZYME ASSAYS; HIGH-THROUGHPUT SCREENING ASSAYS; HISTONE-LYSINE N-METHYLTRANSFERASE; PROTEIN INTERACTION MAPPING; SUBSTRATE SPECIFICITY;

EID: 84880194087     PISSN: 1540658X     EISSN: 15578127     Source Type: Journal    
DOI: 10.1089/adt.2012.480     Document Type: Article

References (57)

1. Luger K, Ma?der A, Richmond RK, Sargent DF, Richmond TJ: Structure of the nucleosome core particle at 2.8A° resolution. Nature 1997;389:251-260.
2. Rea S, Eisenhaber F, O'Carroll D, et al.: Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature 2000;406:593-599.
3. Lund AH, van Lohuizen M: Polycomb complexes and silencing mechanisms. Curr Opin Cell Biol 2004;16:239-246.
4. Feng Q, Wang H, Ng HH, et al.: Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain. Curr Biol 2002;12:1052-1058.
5. Lund AH, van Lohuizen M: Epigenetics and cancer. Genes Dev 2004;18:2315- 2335.
6. Copeland RA, Solomon ME, Richon VM: Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov 2009;8:724-732.
7. Margueron R, Li G, Sarma K, et al.: Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms. Mol Cell 2008;32:503-518.
8. Cao R, Wang L, Wang H, et al.: Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 2002;298:1039-1043.
9. Kuzmichev A, Jenuwein T, Tempst P, Reinberg D: Different EZH2-containing complexes target methylation of histone H1 or nucleosomal histone H3. Mol Cell 2004;14:183-193.
10. Ernst T, Chase AJ, Score J, et al.: Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010;42:722-726.
11. Huang J, Dorsey J, Chuikov S, et al.: G9a and Glp Methylate Lysine 373 in the Tumor Suppressor p53. J Biol Chem 2010;285:9636-9641.
12. Luger K, Ma?der A, Richmond RK, Sargent DF, Richmond TJ: Structure of the nucleosome core particle at 2.8A° resolution. Nature 1997;389:251-260.
13. Rea S, Eisenhaber F, O'Carroll D, et al.: Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature 2000;406:593-599.
14. Lund AH, van Lohuizen M: Polycomb complexes and silencing mechanisms. Curr Opin Cell Biol 2004;16:239-246.
15. Feng Q, Wang H, Ng HH, et al.: Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain. Curr Biol 2002;12:1052-1058.
16. Lund AH, van Lohuizen M: Epigenetics and cancer. Genes Dev 2004;18:2315- 2335.
17. Copeland RA, Solomon ME, Richon VM: Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov 2009;8:724-732.
18. Margueron R, Li G, Sarma K, et al.: Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms. Mol Cell 2008;32:503-518.
19. Cao R, Wang L, Wang H, et al.: Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 2002;298:1039-1043.
20. Kuzmichev A, Jenuwein T, Tempst P, Reinberg D: Different EZH2-containing complexes target methylation of histone H1 or nucleosomal histone H3. Mol Cell 2004;14:183-193.
21. Ernst T, Chase AJ, Score J, et al.: Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010;42:722-726.
22. Huang J, Dorsey J, Chuikov S, et al.: G9a and Glp Methylate Lysine 373 in the Tumor Suppressor p53. J Biol Chem 2010;285:9636-9641
23. Gaughan L, Stockley J, Wang N, et al.: Regulation of the androgen receptor by SET9-mediated methylation. Nucleic Acids Res 2011;39:1266-1279.
24. Okada Y, Feng Q, Lin Y, et al.: hDOT1L links histone methylation to leukemogenesis. Cell 2005;121:167-178.
25. Wolf SS: The protein arginine methyltransferase family: an update about function, new perspectives and the physiological role in humans. Cell Mol Life Sci 2009;66:2109-2121.
26. Krause CD, Yang Z-H, Kim Y-S, Lee J-H, Cook JR, Pestka S: Protein arginine methyltransferases: evolution and assessment of their pharmacological and therapeutical potential. Pharmacol Ther 2007;113:50-87.
27. Trojer P, Dangl M, Bauer I, Graessle S, Loidl P, Brosch G: Histone methyltransferases in Aspergillus nidulans: evidence for a novel enzyme with a unique substrate specificity. Biochemisty 2004;43:10834-10843.
28. Pahlich S, Zakaryan RP, Gehling H: Protein arginine methylation: cellular functions and methods of analysis. Biochim Biophys Acta 2006;1764:1890-1903.
29. Lakowski, TM, Frankel, A: Kinetic analysis of human protein arginine methyltransferase 2: formation of monomethyl and asymmetric dimethylarginine residues on histone 4. Biochem J 2009;421:253-261.
30. Paik WK, Paik DC, Kim S: Historical review: the field of protein methylation. Trends Biochem Sci 2007;32:146-152.
31. Gary JD, Clarke S: RNA and protein interactions modulated by protein arginine methylation. Prog Nucleic Acid Res Mol Biol 1998;61:65-131.
32. Aletta JM, Hu JC: Protein arginine methylation in health and disease. Biotechnol Annu Rev 2008;14:203-224.
33. Bhaumik SR, Smith E, Shilatifard A: Covalent modifications of histones during development and disease pathogenesis. Nat Struct Mol Biol 2007;14:1008-1016.
34. Ma H, Deacon SW, Horiuchi KY: The challenge of selecting protein kinase assays for lead discovery optimization. Expert Opin Drug Discov 2008;3:607-621.
35. Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson JR: Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat Biotech 2011;29:1039-1045.
36. Schnitzler GR: Isolation of Histones and Nucleosome Cores from Mammalian Cells. Current Protocols in Molecular Biology. New York: John Wiley & Sons, Inc., 2000;21.5.1-21.5.12.
37. Luo M: Current chemical biology approaches to interrogate protein methyltransferases. ACS Chem Biol 2012;7:443-463.
38. Tachibana M, Sugimoto K, Fukushima T, Shinkai Y: Set domain-containing protein, G9a, is a novel lysine-preferring mammalian histone methyltransferase with hyperactivity and specific selectivity to lysines 9 and 27 of histone H3. J Biol Chem 2001;276:25309-25317.
39. Fingerman IM, Li H-C, Briggs SD: A charge-based interaction between histone H4 and Dot1 is required for H3K79 methylation and telomere silencing: identification of a new trans-histone pathway. Genes Dev 2007;21:2018-2029.
40. Segel IH: Chapter 9: Steady-state kinetics of multireactant enzymes. In Segel IH (ed): Enzyme Kinetics. New York: John Wiley & Sons Inc., 1975;506-841.
41. Trievel RC, Beach BM, Dirk LMA, Houtz RL, Hurley JH: Structure and catalytic mechanism of a SET domain protein methyltransferase. Cell 2002;111:91-103.
42. Dirk LMA, Flynn EM, Dietzel K, Couture J-F, Trievel RC, Houtz RL: Kinetic manifestation of processivity during multiple methylations catalyzed by SET domain protein methyltransferases. Biochemistry 2007;46:3905-3915.
43. Richon VM, Johnston D, Sneeringer CJ, et al.: Chemogenetic analysis of human protein methyltransferases. Chem Biol Drug Des 2011;78:199-210.
44. Kubicek S, O'Sullivan RJ, August EM, et al.: Reversal of H3K9me2 by a smallmolecule inhibitor for the G9a histone methyltransferase. Mol Cell 2007;25: 473-481.
45. Chang Y, Zhang X, Horton JR, et al.: Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294. Nat Struct Mol Biol 2009;16:312-317.
46. Liu F, Chen X, Allali-Hassani A, et al.: Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4- diamino-7-aminoalkoxy-quinazolines. J Med Chem 2010;53:5844-5857.
47. Zhang JH, Chung TDY, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high-throughput screening assays. J Biomol Screen 1999;4:67-73.
48. Bonaldi T, Regula JT, Imhof A: The use of mass spectrometry for the analysis of histone modifications. Methods Enzymol 2004;377:111-130.
49. Rathert P, Cheng X, Jeltsch A: Continuous enzymatic assay for histone lysine methyltransferases. BioTechniques 2007;43:602-608.
50. Quinn AM, Allali-Hassani A, Vedadi M, Simeonov A: A chemiluminescencebased method for identification of histone lysine methyltransferase inhibitors. Mol BioSyst 2010;6:782-788.
51. Graves TL, Zhang Y, Scott JE: A universal competitive fluorescence polarization activity assay for S-adenosylmethionine utilizing methyltransferases. Anal Biochem 2008;373:296-306.
52. Collazo E, Couture JF, Bulfer S, Trievel RC: A coupled fluorescent assay for histone methyltransferases. Anal Biochem 2005;342:86-92.
53. Wigle TJ, Provencher LM, Norris JL, et al.: Accessing protein methyltransferase and demethylase enzymology using microfluidic capillary electrophoresis. Chem Biol 2010;17:695-704.
54. Hilyard K, Beyer KS, Ahrens T, Bergner A, Fasler S, Hafenbradl D: Epigenetic protein targets: Computational approaches and new assay technologies for efficient hit finding against G9a and LSD1. BioFocus Web Poster www.biofocus.com/-downloads/posters/2012/epigenetic-protein-targets .pdf 44
55. Shinkai Y, Tachibana M: H3K9 methyltransferase G9a and the related molecule GLP. Genes Dev 2011;25:781-788.
56. Ibanez G, Shum D, Blum G, et al.: A high throughput scintillation proximity imaging assay for protein methyltransferases. Comb Chem High Throughput Screen 2012;15:359-371.
57. McGeary RP, Bennett AJ, Tran QB, Cosgrove KL, Ross BP: Suramin: clinical uses and structure-activity relationships. Mini Rev Med Chem 2008;8:1384-1394.